As 2022 gets underway we check in with a crew of seasoned biotech experts on events in Q1 and the key trends to look out for the rest of the year. Sam Falsetti, Global Chief Biotechnology Officer for MEDiSTRAVA, hosts a wide-ranging discussion with two of his executive colleagues. He is joined by Dean McAllister, EVP, Global Biotech Enterprise Solutions from Ashfield

2021 was a wild ride for biotechnology companies and 2022 is shaping up with some interesting trends that will take biotech into both significant headwinds and opportunities. Sam Falsetti, Global Chief Biotechnology Officer for MEDiSTRAVA, hosts a wide-ranging discussion with two of his executive colleagues. He is joined by Phil Wakefield, the Global Chief Advisory and Evidence Communications Officer for the MEDiSTRAVA group, and Rachel Hatfield, a Managing Partner at MEDiSTRAVA Consulting. They discuss a wide array of topics including lessons learned from 2021, crystal ball predictions for 2022, and key trends that biotech executives should take into account when planning for organizational growth and asset development.